Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the afamelanotide (CUV1647) formulation is
effective in preventing PLE episodes or reducing the severity of PLE symptoms in patients
with a well documented history of the disease. The study also aims to determine whether
treatment with afamelanotide (CUV1647) can reduce the use of rescue medication in this group.